Previous close | 6.21 |
Open | 6.21 |
Bid | 6.15 |
Ask | 6.60 |
Strike | 175.00 |
Expiry date | 2025-03-21 |
Day's range | 6.21 - 6.21 |
Contract range | N/A |
Volume | |
Open interest | 98 |
FLOW kidney outcomes trial data evaluating efficacy and safety of once-weekly semaglutide 1.0 mg in people with type 2 diabetes1SELECT cardiovascular outcomes trial data evaluating efficacy and safety of once-weekly semaglutide 2.4 mg in people with obesity and established cardiovascular disease, without diabetes2STEP HFpEF trial programme data evaluating efficacy and safety of once-weekly semaglutide 2.4 mg in people with obesity-related heart failure with preserved ejection fraction (HFpEF), w
Weight-loss breakthroughs all emerged from diabetes treatment. Meetings such as the coming American Diabetes Association are increasingly dominated by news on obesity drugs.
Popular weight-loss drugs have boosted Novo Nordisk and Eli Lilly. After huge gains, the drugmakers' stocks now face this risk.